CDK4/6 inhibitor - Globe Thesis

Keyword [CDK4/6 inhibitor] Result: 21 - 34 \| Page: 2 of 2
21.	Fulvestrant Plus CDK4/6 Inhibitors Or PI3K/mTOR/AKT Inhibitors For HR+/HER2-advanced Breast Cancer That Failed In The First-line Endocrine Therapy:A Meta-analysis
22.	The Efficacy And Safety Of Combination CDK4/6 Inhibitors And Endocrine Therapy For Advanced Breast Cancer:A Meta-analysis
23.	Treatment Of Palbociclib In Hormone Receptor Positive Breast Cancer: A Real-world Study And Efficacy Prediction Model
24.	CDK4/6 Inhibitor,abemaciclib Affects The Malignant Biological Behaviors Of Nasopharyngeal Carcinoma Cells
25.	The Effect And Mechanism Of Aminoquinol,a Novel CDK4/6 Inhibitor,in The Treatment Of Prostate Cancer
26.	Therapeutic Effect And Mechanism Of CDK4/6 Inhibitor Combined With Pd-1 Monoclonal Antibody In Mouse Ovarian Cancer
27.	The Mechanism Of Drug Resistance Of CDK4/6 Inhibitors In The Treatment Of Breast Cancer
28.	The Antitumor Mechanism Of PARP Inhibitor Combined With CDK4/6 Inhibitor In P53-wildtype Gastrointestinal Cancer
29.	Cancer/Testis Antigen MAGEC2 Promotes Resistance To CDK4/6 Inhibitors In HR+/HER2- Breast Cancer By Activating PI3K/AKT/mTOR Pathway
30.	Experimental Study Of The Mechanism Of CDK4/6 Inhibitor SHR6390 Inhibiting The Proliferation Of Cervical Cancer Cells
31.	To Explore The Mechanism Of CDK4/6 Inhibitor Palbociclib Involved In(RB+/CCNE1-)ER+ Positive Breast Cancer Resistance Through Autophagy Activated By MAPK Pathway
32.	Study Of Drug Resistance Genes In CDK4/6 Inhibitor-resistant Luminal-type Breast Cancer
33.	Effects Of CDK4/6 Inhibitor Abemaciclib Combined With Cisplatin On Biological Behavior Of Human Gastric Cancer Cells
34.	CDK4/6 Inhibitor Reverses Acquired Drug Resistance Of PARP Inhibitor In Ovarian Epithelial Carcinoma By Restoring Homologous Recombination Deficiency
<<First <Prev Next> Last>> Jump to